1. Pink Sheet
  2. >>Market Access

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

 
• By Cathy Kelly

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Coronavirus dollar bill
Employer-Sponsored Insurance Could Be Hampered By Pandemic's Cost

It will take longer than previously expected for payers to implement innovative approaches to managing the high cost of cell and gene therapies because of the economic burden imposed by the COVID-19 pandemic, Blue Cross Blue Shield of Massachusetts chief physician executive and senior VP for health and medical management Bruce Nash predicts.

Nash discussed the impact of the COVID-19 outbreak on payers at a Food and Drug Law Institute conference on cell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

AI In Clinical Research: Benefits Across The Board, But ‘Nirvana’ Still Out Of Reach

 
• By Vibha Sharma

Generative artificial intelligence tools, such as ChatGPT, have “democratized” AI, and contract research organizations are wholeheartedly embracing these tools, given their focus on efficiency, says Stephen Pyke, who chairs the AI committee at the Association of Clinical Research Organizations.

Japan Gives Global-First Recommendations To Taisho’s Vornorexant, Santen’s Sepetaprost

 
• By Lisa Takagi

Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.